NDA 018161 · B Braun
Acetic Acid 0.25% In Plastic Container
Acetic Acid, Glacial · Irrigation, Urethral
Last checked: Nov 19, 2026Latest source record: May 15, 2003 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1979
Aug 6, 1979
Approved uses
1
Original approval plus efficacy supplements
Registered trials
210
41 Phase 3, 18 recruiting
FAERS reports
359
283 serious, 28 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Aug 23, 2023.
INDICATIONS AND USAGE 0.25% Acetic Acid Irrigation USP is indicated as a constant or intermittent bladder rinse to help prevent the growth and proliferation of susceptible urinary pathogens (especially ammonia-forming bacteria) in the management of patients who require prolonged placement of an indwelling urethral catheter. It also may be used for periodic irrigation of an indwelling catheter to help maintain patency by reducing the formation of calcium encrustations.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Aug 6, 1979 Original approval · Type 5 - New Formulation or New Manufacturer
1 products under this application
- ACETIC ACID 0.25% IN PLASTIC CONTAINER · ACETIC ACID, GLACIAL 250MG/100ML · SOLUTION, IRRIGATION, URETHRAL · Prescription · TE AT
Clinical trials
Interventional ClinicalTrials.gov studies with "Acetic Acid" as an intervention, any sponsor and status, largest first.
- The Mother-Daughter Project: Merck-4Recruiting
Indiana UniversityAcademic, hospital or other
NCT07240220 · 2,500 participants (planned) · Start Jul 22, 2026 · Primary completion Aug 1, 2028
Drug: Gardasil-9 · For: Cervical Dysplasia
Sites: Eldoret, Kenya
- A Cervical Cancer Prevention Program in KenyaActive, not recruiting
Indiana UniversityAcademic, hospital or other
NCT06411938 · 2,300 participants (planned) · Start Apr 2, 2024 · Primary completion Dec 31, 2026
Drug: Gardasil-9 · For: Cervical Cancer Prevention; Cervical Cancer
Sites: Eldoret, Kenya
- Safety and Efficacy of Lapaquistat Acetate Taken Alone and With Atorvastatin in Subjects With Primary DyslipidemiaPivotal-lookingCompleted
TakedaTakeda (TAK)
NCT00487994 · 2,130 participants · Start Nov 2004 · Primary completion May 2007
Drug: Lapaquistat acetate; Lapaquistat acetate and atorvastatin and 1 more · For: Dyslipidemia
Sites: Birmingham, Alabama; Mobile, Alabama; Northport, Alabama · 128 sites in all
- Efficacy of Lapaquistat Acetate Alone or Combined With Simvastatin in Subjects With HypercholesterolemiaPivotal-lookingCompleted
TakedaTakeda (TAK)
NCT00286481 · 1,362 participants · Start Mar 2006 · Primary completion May 2007
Drug: Lapaquistat acetate and simvastatin; Lapaquistat acetate and simvastatin and 1 more · For: Hypercholesterolemia
Sites: Huntsville, Alabama; Chandler, Arizona; Scottsdale, Arizona · 67 sites in all
- Efficacy of Lapaquistat Acetate Alone and With Ezetimibe in Subjects With Primary Dyslipidemia.Pivotal-lookingCompleted
TakedaTakeda (TAK)
NCT00268697 · 1,267 participants · Start Oct 2005 · Primary completion Jan 2007
Drug: Lapaquistat acetate; Lapaquistat acetate and ezetimibe and 1 more · For: Hypercholesterolemia
Sites: Tallinn, Estonia; Tartu, Estonia; Riga, Latvia · 9 sites in all
- Trial to Assess Chelation Therapy 2Pivotal-lookingCompleted
Mt. Sinai Medical Center, MiamiAcademic, hospital or other
NCT02733185 · 1,000 participants · Start Oct 1, 2016 · Primary completion Jun 30, 2023
Drug: disodium EDTA; Placebo disodium EDTA · For: Diabetes; Myocardial Infarction
Sites: Miami Beach, Florida
- Use Misoprostol to Optimize Prevention of Cervical CancerPivotal-lookingRecruiting
University of Alabama at BirminghamAcademic, hospital or other
NCT06669533 · 840 participants (planned) · Start Feb 25, 2025 · Primary completion Nov 4, 2027
Drug: Placebo; Misoprostol · For: Cervical Cancers
Sites: Yaoundé, Cameroon
- ReVeRA-301: Etripamil in Atrial Fibrillation Phase 3Pivotal-lookingRecruiting
Milestone Pharmaceuticals Inc.Academic, hospital or other
NCT06716021 · 750 participants (planned) · Start Aug 20, 2026 · Primary completion Dec 2028
Drug: Placebo; Etripamil · For: Atrial Fibrillation
Sites: Vista, California; West Hills, California; Littleton, Colorado · 23 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- nausea41
- diarrhoea33
- toxicity to various agents33
- cough27
- dyspnoea25
- pain24
- coronary artery disease22
- drug ineffective21
- off label use21
- arthralgia20
- nasopharyngitis20
- cardiac disorder19
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 2 |
| 2005 | 4 |
| 2006 | 5 |
| 2007 | 2 |
| 2008 | 3 |
| 2009 | 3 |
| 2010 | 2 |
| 2011 | 8 |
| 2012 | 9 |
| 2013 | 7 |
| 2014 | 11 |
| 2015 | 11 |
| 2016 | 22 |
| 2017 | 13 |
| 2018 | 37 |
| 2019 | 31 |
| 2020 | 15 |
| 2021 | 24 |
| 2022 | 38 |
| 2023 | 41 |
| 2024 | 25 |
| 2025 | 17 |
| 2026 | 29 |
Recalls
1 FDA enforcement reports for this application.
Dec 15, 2017 · Class II · Terminated
Presence of Particulate Matter: identified as polyethylene, which is consistent with the material used to manufacture the contain cap
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Vinegar consumption can attenuate postprandial glucose and insulin responses; a systematic review and meta-analysis of clinical trials.
Shishehbor F, Mansoori A, Shirani F · Diabetes Res Clin Pract 2017 · Meta-Analysis, Systematic Review
- Vinegar intake reduces body weight, body fat mass, and serum triglyceride levels in obese Japanese subjects.
Kondo T, Kishi M, Fushimi T, et al. · Biosci Biotechnol Biochem 2009 · Randomized Controlled Trial
- The Role of Dietary Fibre in Modulating Gut Microbiota Dysbiosis in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomised Controlled Trials.
Ojo O, Feng QQ, Ojo OO, et al. · Nutrients 2020 · Meta-Analysis, Systematic Review
- Effects of a Synbiotic on Plasma Immune Activity Markers and Short-Chain Fatty Acids in Children and Adults with ADHD-A Randomized Controlled Trial.
Yang LL, Stiernborg M, Skott E, et al. · Nutrients 2023 · Randomized Controlled Trial
- The Impact of Fermented Milk Products Containing Bifidobacterium longum BB536 on the Gut Environment: A Randomized Double-Blind Placebo-Controlled Trial.
Ejima R, Mishima R, Sen A, et al. · Nutrients 2024 · Randomized Controlled Trial
- Fecal microbiota transplantation in obesity metabolism: A meta analysis and systematic review.
Zecheng L, Donghai L, Runchuan G, et al. · Diabetes Res Clin Pract 2023 · Meta-Analysis, Systematic Review
Sponsor: B Braun
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.